These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2868491)
21. Modulation of acetylcholine release by cholecystokinin in striatum: receptor specificity; role of dopaminergic neuronal activity. Petkova-Kirova P; Giovannini MG; Kalfin R; Rakovska A Brain Res Bull; 2012 Dec; 89(5-6):177-84. PubMed ID: 22981453 [TBL] [Abstract][Full Text] [Related]
22. Ceruletide for schizophrenia: a double-blind study. Mattes JA; Hom W; Rochford JM; Orlosky M Biol Psychiatry; 1985 May; 20(5):533-8. PubMed ID: 2859054 [TBL] [Abstract][Full Text] [Related]
23. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Hökfelt T; Rehfeld JF; Skirboll L; Ivemark B; Goldstein M; Markey K Nature; 1980 Jun; 285(5765):476-8. PubMed ID: 6105617 [TBL] [Abstract][Full Text] [Related]
24. Clinical and neuroendocrine studies with cholecystokinin peptides. Nair NP; Bloom D; Lal S; Debonnel G; Schwartz G; Mosticyan S Ann N Y Acad Sci; 1985; 448():535-41. PubMed ID: 2862831 [No Abstract] [Full Text] [Related]
25. Subcortical limbic 3H-N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro. Agnati LF; Fuxe K Biosci Rep; 1983 Dec; 3(12):1101-5. PubMed ID: 6320923 [TBL] [Abstract][Full Text] [Related]
26. Modulation of cholecystokinin release from posterior nucleus accumbens by D-2 dopamine receptor. Martin JR; Beinfeld MC; Wang RY Brain Res; 1986 Nov; 397(2):253-8. PubMed ID: 2948613 [TBL] [Abstract][Full Text] [Related]
27. Dopamine receptors, neuroleptics, and schizophrenia. Snyder SH Am J Psychiatry; 1981 Apr; 138(4):460-4. PubMed ID: 6111227 [TBL] [Abstract][Full Text] [Related]
28. Influence of cholecystokinin on central monoaminergic pathways. Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717 [TBL] [Abstract][Full Text] [Related]
29. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents. Van Ree JM; Gaffori O; De Wied D Eur J Pharmacol; 1983 Sep; 93(1-2):63-78. PubMed ID: 6138272 [TBL] [Abstract][Full Text] [Related]
30. Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis. Ballaz SJ; Bourin M Curr Neuropharmacol; 2021; 19(7):925-938. PubMed ID: 33185164 [TBL] [Abstract][Full Text] [Related]
31. Release of cholecystokinin in the central nervous system. Raiteri M; Paudice P; Vallebuona F Neurochem Int; 1993 Jun; 22(6):519-27. PubMed ID: 8513278 [TBL] [Abstract][Full Text] [Related]
32. Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8). Murphy RB; Schuster DI Peptides; 1982; 3(3):539-43. PubMed ID: 6289286 [TBL] [Abstract][Full Text] [Related]